Sarepta Therapeutics (SRPT) Net Cash Flow (2010 - 2026)

Sarepta Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$336.8 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 60.93% year-over-year to -$336.8 million in Q1 2026; TTM through Mar 2026 was $221.1 million, a 218.62% increase from a year earlier, with the FY2025 full-year figure at -$304.2 million, down 145.09% from the prior year.
• Net Cash Flow eased to -$336.8 million in Q1 2026 per SRPT's latest filing, from $188.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $905.2 million in Q4 2024 and bottomed at -$882.0 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$71.8 million (2022), against an average of -$96.9 million.
• Across the five-year window, Net Cash Flow jumped 873.16% in 2024 and sank 75526.58% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$71.8 million in 2022, then tumbled by 62.95% to -$117.1 million in 2023, then soared by 873.16% to $905.2 million in 2024, then slumped by 79.21% to $188.2 million in 2025, then sank by 278.97% to -$336.8 million in 2026.
• Per Business Quant, the three latest SRPT Net Cash Flow figures stand at -$336.8 million (Q1 2026), $188.2 million (Q4 2025), and $100.0 million (Q3 2025).